ELVN
Enliven Therapeutics Inc

1,244
Loading...
Loading...
News
all
press releases
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·14d ago
News Placeholder
More News
News Placeholder
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·17d ago
News Placeholder
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·1mo ago
News Placeholder
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’
Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.
Stocktwits·3mo ago
News Placeholder
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...
PR Newswire·7mo ago
News Placeholder
Mizuho refreshes its US top picks list for January
Investing.com -- Mizuho (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.
investing.com·9mo ago
News Placeholder
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire...
PR Newswire·11mo ago
News Placeholder
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024...
PR Newswire·11mo ago
News Placeholder
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket PR Newswire VANCOUVER, BC, Oct. 4, 2024 USA News Group...
PR Newswire·1y ago

Latest ELVN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.